Mitochondrial Dysfunctions Contribute to Hypertrophic Cardiomyopathy in Patient iPSC-Derived Cardiomyocytes with MT-RNR2 Mutation

Shishi Li,1,2,13 Huaye Pan,1,13 Chao Tan,3,13 Yaping Sun,1 Yanrui Song,1 Xuan Zhang,1 Wei Yang,1 Xuexiang Wang,1 Dan Li,1 Yu Dai,1 Qiang Ma,1 Chenming Xu,1 Xufen Zhu,1 Lijun Kang,5 Yong Fu,1,6 Xuejun Xu,7 Jing Shu,2 Naiming Zhou,1 Feng Han,3 Dajiang Qin,8 Wendong Huang,9,* Zhong Liu,10,* and Qingfeng Yan11,12,14,*

1College of Life Science, Zhejiang University, Hangzhou, Zhejiang 310058, China
2Department of Reproductive Endocrinology, Zhejiang Provincial People’s Hospital, Hangzhou, Zhejiang 310014, China
3College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China
4International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
5School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, China
6The Children’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310052, China
7Stomatology Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China
8Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong 510530, China
9Department of Diabetes Complications and Metabolism, The Beckman Research Institute, City of Hope National Medical Center, Duarte, CA 91010, USA
10The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, China
11Institute of Genetics, Zhejiang University, Hangzhou, Zhejiang 310058, China
12Key Laboratory for Cell and Gene Engineering of Zhejiang Province, Hangzhou, Zhejiang 310058, China
13Co-first author
14Lead contact

*Correspondence: whuang@coh.org (W.H.), liuzhong_68@hotmail.com (Z.L.), qfyan@zju.edu.cn (Q.Y.)

https://doi.org/10.1016/j.stemcr.2018.01.013

SUMMARY

Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death in young individuals. A potential role of mtDNA mutations in HCM is known. However, the underlying molecular mechanisms linking mtDNA mutations to HCM remain poorly understood due to lack of cell and animal models. Here, we generated induced pluripotent stem cell-derived cardiomyocytes (HCM-iPSC-CMs) from human patients in a maternally inherited HCM family who carry the m.2336T>C mutation in the mitochondrial 16S rRNA gene (MT-RNR2). The results showed that the m.2336T>C mutation resulted in mitochondrial dysfunctions and ultrastructural defects by decreasing the stability of 16S rRNA, which led to reduced levels of mitochondrial proteins. The ATP/ADP ratio and mitochondrial membrane potential were also reduced, thereby elevating the intracellular Ca2+ concentration, which was associated with numerous HCM-specific electrophysiological abnormalities. Our findings therefore provide an innovative insight into the pathogenesis of maternally inherited HCM.

INTRODUCTION

Hypertrophic cardiomyopathy (HCM) is a primary myocardial disease characterized by left ventricle and asymmetric septal hypertrophy. It is the most common cause of sudden cardiac death in young individuals, affecting approximately 0.2% of the population (Hershberger et al., 2009; Maron et al., 2006). Familial HCM is mainly inherited as an autosomal dominant trait by mutations in sarcomeric genes (Alcalai et al., 2008; Morita et al., 2008). The maternal transmission of HCM has also been implicated in some pedigrees, suggesting that mtDNA mutations could contribute to this disorder (Bates et al., 2012; Song et al., 2011). However, the underlying molecular mechanisms by which mtDNA mutations contribute to HCM remain elusive due to lack of cell and animal models.

The mitochondrion is a semiautonomous organelle and contains its own genome (mtDNA), encoding for 13 subunits of complexes I, III, IV, and V of the electron transport chain (ETC) as well as 22 tRNAs and 2 rRNAs necessary for mitochondrial translational machinery. mtDNA mutations often lead to mitochondrial dysfunctions and contribute to mitochondrial disorders (Taylor and Tumbull, 2005; Wallace et al., 1988). Cardiomyopathy is one of the most common clinical manifestations in mitochondrial diseases (Finsterer and Kothari, 2014). Since the m.3260A>G mutation in the MT-TL1 gene was identified to be associated with HCM (Zeviani et al., 1991), several other mutations have been reported in mitochondrial tRNA genes such as MT-TG (Merante et al., 1994), MT-TK (Santorelli et al., 1996), MT-TH (Shin et al., 2000), and MT-TI (Taylor et al., 2003) and in mitochondrial protein-encoding genes such as MT-CYB (Andreu et al., 2000), MT-ATP8 (Jonckheere et al., 2008), and MT-ATP6 (Ware et al., 2009). These mtDNA mutations result in some defects of mitochondrial functions and ultrastructures (Merante et al., 1994; Liu et al., 2014). Clinical and experimental studies have shown that abnormal energy metabolism is a common event in HCM pathogenesis (Pisano et al., 2016; Rosca et al., 2013; Luedde et al., 2009). The primary cardiomyocytes from patients are...
difficult to obtain due to ethical issues, biopsy inaccessibility, and culture span limitations. Previous studies were mainly performed using patient samples such as skin fibroblasts, lymphocytes, and transferring mitochondria cell lines (cybrids). However, these cells could not provide direct evidence of the impact of mtDNA mutations on the pathogenesis of HCM, because different tissues may show different susceptibilities to specific mtDNA mutations (Wu et al., 2016; Wallace and Fan, 2009; Zhang et al., 2014).

Recently, patient-specific induced pluripotent stem cells (iPSCs) have attracted great attention for their unique advantages in elucidating the mechanisms underlying mitochondrial disorders (Inoue et al., 2014; Yamanaka, 2007). Since each mammalian cell contains hundreds of double-membrane mitochondria and each mitochondrion contains multiple copies of mtDNA molecules, it is impossible to directly generate cellular and animal models with targeted mtDNA mutations by using plasmid transfecting or gene editing technology. Generation of patient-specific iPSCs circumvent the above technical hurdles and make reprogramming donor cells carrying mtDNA defects available. iPSCs from patients with mutations in the nuclear DNA (nDNA) have been widely established. iPSC-derived cardiomyocytes carrying mutations in sarcomeric genes possessed the characteristics of the HCM phenotype at the single-cell level (Lan et al., 2013; Birket et al., 2015). To date, only a few studies have been reported to reprogram iPSCs from patients with mtDNA mutations, such as Pearson marrow pancreas syndrome with mtDNA deletion (Cherry et al., 2013), diabetes mellitus with m.3243A>G mutation in tRNA Leu(UUR) (Fujikura et al., 2012), and mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes with m.3243A>G mutation in tRNA Leu(UUR) (Hamalainen et al., 2013). These studies indicated that the patient iPSCs contain a similar range of mtDNA heteroplasmy for disease-causing mutations (Cherry et al., 2013; Holmes et al., 2013), and iPSC-derived cells manifest cell-type-specific patterns of respiratory chain deficiency (Hamalainen et al., 2013). Genetically rescued patient iPSCs display normal metabolic function, compared with the impaired oxygen consumption and ATP production observed in mutant cells (Ma et al., 2015). However, studies on HCM-specific iPSCs with mtDNA mutations have not been reported yet.

We previously identified the m.2336T>C mutation in the MYOT-RNR2 gene from a Chinese maternally inherited HCM family (Liu et al., 2014). This mutation disturbed conserved 2336U-A2438 base pairing in the domain III stem-loop structure of mitochondrial ribosome 16S rRNA, resulting in mitochondrial dysfunctions in the immortalized lymphoblastoid cell lines (Liu et al., 2014). In this report, we generated patient-specific iPSCs as well as their derived cardiomyocytes as a disease model to understand the pathogenic mechanism of maternally inherited HCM.

RESULTS

Establishment and Identification of HCM-iPSCs Carrying the m.2336T>C Mutation

We previously reported the clinical, genetic, and molecular characterization of a four-generation HCM family (Liu et al., 2014). Mutational analysis of the mitochondrial genome identified the m.2336T>C mutation, which was presented exclusively in all the maternal members. The clinical features of the HCM family members are summarized in Table S1. The proband of this family was affected with severe non-obstructive HCM, left ventricular remodeling, and implanted permanent pacemaker. His echocardiography parameters were as follows: maximum left ventricular wall thickness, 37.4 mm; interventricular septum thickness, 28.7 mm; and interventricular septum/left posterior wall ratio, 3.99.

Urine cells ([UCs] epithelial-like cells detached from tubules) from the proband (III-3) in the HCM family (HCM-UCs), and from healthy controls (Con-UCs) including the proband’s son (IV-2) and two genetically unrelated individuals in the same region, were collected and cultured for approximately 2 weeks. The UCs were then infected with retroviral vectors containing Oct4, Sox2, Klf4, and c-Myc. After induction for 25–30 days, 20 clones of HCM-specific iPSCs (HCM-iPSCs) from the proband and 10 clones of iPSCs from each control individual (Con-iPSCs) were selected. These iPSCs were tightly packed and grown in colonies that were positively stained for alkaline phosphatase (Figure S1A). Immunofluorescence analysis of iPSCs confirmed positive signals for embryonic stem cell (ESC) marker proteins, including TRA-1-60, TRA-1-81, SSEA-3, SSEA-4, and NANOG (Figure S1A). Expression of endogenous pluripotency genes (OCT4, SOX2, NANOG, and REX-1) were similar to those in ESCs but significantly higher than those in UCs (Figure S2A). Expression of exogenous reprogramming factors (OCT4, SOX2, KLF4, and C-MYC) was silenced (Figure S2B) and integrated into iPSC genomes (Figure S2C). The methylation levels of pluripotency gene (OCT4 and NANOG) promoters were also similar to those in ESCs but significantly lower than those in UCs (Figure S2D). Karyotype analysis showed that iPSCs exhibited normal chromosomal morphology, number, and integrity (Figure S2E). Embryoid body and teratoma formation assays yielded cellular derivatives of ectodermal, mesodermal, and endodermal cells both in vitro (Figure S1B) and in vivo (Figure S1C), confirming the pluripotent nature of the generated iPSCs. We next analyzed the sequence of the complete mitochondrial genome from the HCM-iPSCs at the 10th, 23rd, and 33rd passages. The results confirmed the presence of the m.2336T>C mutation (Figure S3) and the absence of any other novel mtDNA mutations (Table S2). These results
indicated that we successfully established patient-specific HCM-iPSCs.

**Differentiation of HCM-iPSCs into HCM-iPSC-CMs**

We employed a modified monolayer myocardial differentiation protocol (Figure 1A) to generate cardiomyocytes (iPSC-CMs). Spontaneously beating cardiomyocytes were observed on days 8–12 after the induction of differentiation. By day 40, mature cardiomyocytes were obtained for functional analysis. These cardiomyocytes were maintained as spontaneously beating cells in culture for more than 4 months. The differentiation efficiency of cardiomyocytes exceeded 90%. HCM-iPSC-CMs displayed a disorder of rhythmic beating (Movie S1), whereas Con-iPSC-CMs displayed persistent and spontaneous rhythmic beating (Movie S2). Based on cardiac troponin I (TNNI3), MLC2v, and MLC2a in HCM-iPSC-CMs and Con-iPSC-CMs. Nuclei are stained in blue with DAPI. Scale bar, 100 μm. (C) Western blotting and quantification analysis of α-ACTIN, cardiac troponin I (TNNI3), MLC2v, and MLC2a. β-ACTIN is shown as a loading control. Data are represented as mean ± SEM. *p < 0.05, **p < 0.01.

**Figure 1. Differentiation and Identification of iPSC-CMs**

(A) Schematic of cardiomyocyte differentiation protocol.

(B) Representative immunostaining for α-ACTIN, cardiac troponin I (TNNI3), MLC2v, and MLC2a in HCM-iPSC-CMs and Con-iPSC-CMs. Nuclei are stained in blue with DAPI. Scale bar, 100 μm.

(C) Western blotting and quantification analysis of α-ACTIN, cardiac troponin I (TNNI3), MLC2v, and MLC2a. β-ACTIN is shown as a loading control. Data are represented as mean ± SEM. *p < 0.05, **p < 0.01.

Next, cell size was measured using the ImageJ 3D Objects Counter plugin under a laser scanning confocal microscope. Based on TNNI3 immunostaining, the average size of HCM-iPSC-CMs was approximately 27% larger than that of the Con-iPSC-CMs (Figure 2A). Immunostaining and western blotting showed that the expression of other HCM marker proteins such as ANF, BNP, and NFATC4 in HCM-iPSC-CMs was significantly higher than in Con-iPSC-CMs (Figures 2B and 2C). In addition, cardiomyocytes with positive nuclear NFATC4 staining were also...
significantly higher in HCM-iPSC-CMs (43.1%, n = 51) than in Con-iPSC-CMs (26.1%, n = 46) (p < 0.05) (Figure 2B). These results indicated that the m.2336T>C mutation did not alter the directional differentiation from HCM-iPSCs into HCM-iPSC-CMs but that HCM-iPSC-CMs might possess some major histopathological features of hypertrophied cardiomyocytes and provide a model to understand the pathological mechanism of maternally inherited HCM.

Defects in Mitochondrial Ultrastructure
To determine whether the m.2336T>C mutation affects mitochondrial morphology, we used transmission electron microscopy (TEM) to examine the mitochondrial ultrastructure. As expected, we observed some changes in the mitochondrial structure within undifferentiated and differentiated cells. For control samples, the reprogrammed Con-iPSCs exhibited immature rounded mitochondria with rare cristae as well as an expanded matrix. The differentiated Con-iPSC-CMs showed few mature elongated mitochondria with many well-defined cristae and a compacted matrix (Figure 3A). However, for patient samples, HCM-iPSCs exhibited immature rounded mitochondria with underdeveloped cristae and few elongated mitochondria with developed cristae (Figure 3A), while mitochondrial number was significantly increased in comparison with that in

**Figure 2. Identification of Hypertrophied Characteristics of HCM-iPSC-CMs**
(A) 3D fluorescent images showing the cell size of HCM-iPSC-CMs and Ctrl-iPSC-CMs by the ImageJ 3D Objects Counter plugin under laser scanning confocal microscope. Quantification of cell size in HCM-iPSC-CMs (n = 52) compared with that in Con-iPSC-CMs (n = 63).
(B) Representative immunostaining for ANF, BNP, and NFATC4 in HCM-iPSC-CMs and Con-iPSC-CMs. Nuclei are stained in blue with DAPI.
(C) Western blotting and quantification analysis of ANF, BNP, and NFATC4. β-ACTIN is shown as a loading control. Data are represented as mean ± SEM. *p < 0.05, **p < 0.01.
controls (Figure 3C). The length of the mitochondrial maximal axis significantly decreased during reprogramming and then markedly increased upon differentiation in control cells, whereas no similar changes were detected in patient cells (Figure 3B). These findings indicated that the m.2336T>C mutation impaired the mitochondrial morphology during cardiomyocyte differentiation.

Reduction in the Stability of 16S rRNA and Mitochondrial Translation

To determine whether the m.2336T>C mutation has effects on mitochondrial gene expression, we examined the mtDNA copy number, levels of 16S rRNA, and mitochondrial translation from three cell lines for HCM-iPSCs, Con-iPSCs, HCM-iPSC-CMs, and Con-iPSC-CMs. The average mtDNA copy number in HCM-iPSC-CMs was 1,236 ± 107 compared with 722 ± 51 in Con-iPSC-CMs. Consistent with the mitochondrial content via TEM observations, mtDNA copy number in HCM-iPSC-CMs was significantly increased by 71.2% in comparison with Con-iPSC-CMs (p < 0.05) (Figure 4A). It was also consistent with the situation of primary samples, such as UCs, from HCM patients and normal controls. The steady-state levels of mitochondrial 16S rRNA were measured by qPCR and normalized to the average levels in the same cell lines for the reference VDAC (a nuclear-encoded outer mitochondrial membrane protein). The average level of 16S rRNA in HCM-iPSC-CMs was significantly decreased by 55% (p < 0.01) compared with that in Con-iPSC-CMs (Figure 4B). A western blot analysis was performed to examine the

Figure 3. Mitochondrial Morphology in iPSCs and iPSC-CMs

(A) Transmission electron microscopy (TEM) was used to investigate the mitochondrial morphology changes during reprogramming and differentiation. The arrows show mitochondria. (B) Morphometric analysis of mitochondrial length in HCM-iPSCs (n = 55), Con-iPSCs (n = 50), HCM-iPSC-CMs (n = 40), and Con-iPSC-CMs (n = 40). (C) Relative mitochondrial content in HCM-iPSC-CMs (n = 40) compared with Con-iPSC-CMs (n = 40). Data are represented as mean ± SEM. *p < 0.05, **p < 0.001.
steady-state levels of mitochondrial 16S rRNA binding proteins and some ETC complex subunits with VDAC as a loading control. The relative levels of mitochondrial 16S rRNA binding proteins were significantly decreased in the mutant cell lines compared with those of the controls: the steady-state levels of MRPL19 and MRPL23 in HCM-iPSC-CMs were 51.1% (p < 0.01) and 23.8% (p < 0.01) of those in Con-iPSC-CMs, respectively (Figure 4C). The average levels of mtDNA-encoded ETC complex subunits, such as p.MT-ND5 (subunit 5 of NADH dehydrogenase), p.MT-CYB (cytochrome b), p.MT-COX2 (subunit 2 of cytochrome c oxidase), and p.MT-ATP8 (subunit 8 of H+-ATPase) in HCM-iPSC-CMs were 59% (p < 0.01), 73% (p > 0.05), 84% (p < 0.05), and 54% (p < 0.01) of those in Con-iPSC-CMs. However, there were no significant differences in the mtDNA copy number and average levels of mitochondrial translation between HCM-iPSCs and Con-iPSCs (Figure 4D). These results indicated that the m.2336T>C mutation decreased the stability of 16S rRNA and the steady-state levels of its binding proteins, impaired mitochondrial ribosomal assembly, and led to reduced levels of mitochondrial proteins in HCM-iPSC-CMs.

**Reduction in the Mitochondrial Membrane Potential and ATP/ADP Ratio**

The mitochondrial membrane potential (Δψm) is a key indicator of the integrity of mitochondrial structure and function. The relative ratios of FL590/FL525 geometric mean between mutant and control cell lines were calculated to show the level of Δψm. Carbonyl cyanide 3-chlorophenylhydrazone (CCCP) was used as a protonophore uncoupler to allow for maximum proton (H+) flux through the ETC. The Δψm drove complex V of the ETC to synthesize ATP. In the absence of CCCP, the level of Δψm in HCM-iPSC-CMs was 75% (p < 0.05) of that in
Con-iPSC-CMs (Figure 4A). In the presence of CCCP, the levels of Δψm in mutant cells were comparable with those in the control cell lines (p > 0.05) (Figure 5A). The decreased Δψm could reduce the ATP generation capacity, which was consistent with the observation of a 47% (p < 0.01) ATP/ADP ratio in HCM-iPSC-CMs relative to that in Con-iPSC-CMs (Figure 5B). These results indicate that the defective ETC complexes by the m.2336T>C mutation led to mitochondrial dysfunctions, including reduction of mitochondrial membrane potential and the ATP/ADP ratio.

Abnormal Ca\(^{2+}\) Homeostasis and L-type Ca\(^{2+}\) Current

Calcium (Ca\(^{2+}\)) plays a fundamental role in the regulation of electrophysiological signaling in cardiomyocyte (Bers, 2008). To determine whether the m.2336T>C mutation affects intracellular Ca\(^{2+}\) homeostasis, we compared intracellular Ca\(^{2+}\) concentration ([Ca\(^{2+}\)]\text{i}) and L-type Ca\(^{2+}\) current (\(\text{I}_{\text{CaL}}\)) between HCM-iPSC-CMs and Con-iPSC-CMs. [Ca\(^{2+}\)]\text{i} in HCM-iPSC-CMs was 213 ± 14 nmol/L, significantly higher than 131 ± 14 nmol/L in Con-iPSC-CMs (p < 0.05) (Figure 6A). Representative Ca\(^{2+}\) transient traces were performed using fura-2-acetoxyethyl ester (fura-2AM) and exposed to caffeine, which induces release of sarcoplasmic reticulum (SR) Ca\(^{2+}\) stores into the cytoplasm (Figure 6B). Different from previous reports (Lan et al., 2013), HCM-iPSC-CMs exhibited significantly elevated SR Ca\(^{2+}\) release compared with Con-iPSC-CMs (Figure 6C). The steady-state level of mitochondrial calcium uniporter (MCU) in HCM-iPSC-CMs was decreased by 40% (p < 0.01) compared with that in Con-iPSC-CMs (Figure S5). The expression analysis of some Ca\(^{2+}\) transport marker proteins, such as SERCA, NCX, and PLB, showed no significant difference between Con-iPSC-CMs and HCM-iPSC-CMs (Figure S6A). The PLB/p/PLB ratio in Con-iPSC-CMs and HCM-iPSC-CMs also showed no significant difference (Figure S6B). These results also confirmed that the increment of [Ca\(^{2+}\)]\text{i} was not due to reduced uptake of Ca\(^{2+}\) by the SR. Next, we measured \(\text{I}_{\text{CaL}}\) of cardiomyocytes by whole-cell patch clamping at −60 to +50 mV (Figure 6D). The average cell capacitance (Cm) of HCM-iPSC-CMs (46.1 ± 3.9 pF) was significantly larger than that of Con-iPSC-CMs (28.7 ± 2.1 pF) (Figure 6E). The maximal \(\text{I}_{\text{CaL}}\) was −138 ± 56 pA in HCM-iPSC-CMs at 0 mV, which was a 42.9% (p < 0.01) reduction compared with −242 ± 60 pA in the Con-iPSC-CMs (Figures 5F and 6G). Accordingly, normalized by Cm, the maximal density of \(\text{I}_{\text{Cal}}\) was −4.52 ± 0.58 pA/pF in HCM-iPSC-CMs at 0 mV, which was a 57.2% (p < 0.01) reduction compared with −10.55 ± 0.73 pA/pF in the Con-iPSC-CMs (Figures 6H and 6I). Moreover, steady-state activation and inactivation of the \(\text{I}_{\text{CaL}}\) were tested and investigated. The results showed that there was a remarkable voltage-positive shift for the activation curve, with a \(V_{1/2}\) elevation from −28.6 ± 1.5 mV in Con-iPSC-CMs to −23.6 ± 1.6 mV in HCM-iPSC-CMs (Figure 6J and Table S3), while for the inactivation curve, no marked difference was observed (Figure 6K and Table S3). These results indicated that the m.2336T>C mutation caused the reduction of mitochondrial membrane potential and then led to the increased [Ca\(^{2+}\)]\text{i}, and decreased \(\text{I}_{\text{Cal}}\) density in HCM-iPSC-CMs.

Abnormal Electrophysiological Properties

The electrophysiological properties of the cardiomyocytes were examined by whole-cell patch clamping (Table S4). The HCM-iPSC-CMs exhibited delayed afterdepolarizations (DADs) more frequently (Figure 7A), which failed to trigger action potentials (APs) and clustered beats. Cells with putative DADs were 32.6% ± 6.7% in HCM-iPSC-CMs and 10.0% ± 3.8% in Con-iPSC-CMs, whereas DAD rates were 4.8 ± 0.8 in HCM-iPSC-CMs and 1.4 ± 0.5 in Con-iPSC-CMs (Figure 7B). Representative APs were recorded from HCM-iPSC-CMs and Con-iPSC-CMs (Figure 7C). Statistical analysis indicated that the action potential duration (APD) of the HCM-iPSC-CMs was approximately 21% (p < 0.01), 17% (p < 0.01), and 14% (p < 0.01) longer than that of Con-iPSC-CMs at the 30% repolarization (APD30), 50% repolarization (APD50), and 90% repolarization (APD90) stage, respectively (Figure 7D). There was no significant difference in the maximum (Max) velocity of phase 0 depolarization (dV/dt Max) (Figure 7E), resting membrane potential (Figure 7F), and AP amplitude.
Figure 6. Ca\(^{2+}\) Handling Properties of HCM-iPSC-CMs

(A) Quantification of [Ca\(^{2+}\)]\(_i\) was measured on a fluorescence spectrometer by staining with fura-2 AM fluorescence dye.

(B) Representative Ca\(^{2+}\) transient traces from HCM-iPSC-CMs (n = 65) and Con-iPSC-CMs (n = 58) followed by caffeine exposure.

(C) Mean peak amplitudes of ΔF/F0 ratios after caffeine administration representing release of SR Ca\(^{2+}\) load for HCM-iPSC-CMs (n = 65) and Con-iPSC-CMs (n = 58).

(D) Representative traces for \(I_{CaL}\) using whole-cell patch clamp from HCM-iPSC-CMs (n = 36) and Con-iPSC-CMs (n = 38).

(E) Cell capacitance measurements of cell size using patch clamp for HCM-iPSC-CMs (n = 34) and Con-iPSC-CMs (n = 39).

(F) Current-voltage relationship of \(I_{CaL}\) was determined from −60 to +50 mV in 10-mV increments from HCM-iPSC-CMs (n = 36) and Con-iPSC-CMs (n = 38).

(G) Mean peak of \(I_{CaL}\) in HCM-iPSC-CMs (n = 36) and Con-iPSC-CMs (n = 38). Peak \(I_{CaL}\) was determined as the difference between the peak inward current and baseline current at the end of depolarization.

(legend continued on next page)
(Figure 7G) between HCM-iPSC-CMs and HCM-iPSC-CMs. The potassium currents in both control and HCM-iPSC-CMs were also measured via whole-cell patch clamping (Figure S7A). Although different from maximal $I_{\text{CaL}}$, the maximal $I_k$ showed no significant difference between HCM-iPSC-CMs (151.6 ± 29.0 pA) and Con-iPSC-CMs (119.4 ± 12.9 pA) (Figures S7B and 7C). Similar to maximal density of $I_{\text{CaL}}$, the maximal density of $I_k$ was 2.3 ± 0.4 pA/pF in HCM-iPSC-CMs, which was a 58.9% (p < 0.01) reduction compared with 5.6 ± 0.7 pA/pF in the Con-iPSC-CMs (Figures S7D and 7E). The prolongation of the APD at 30%, 50%, and 90% of the repolarization phase might result from multi-components of the AP contour, including $I_{\text{CaL}}$ and $I_k$. These results suggest that HCM-iPSC-CMs with the m.2336T>C mutation exhibited some cell-specific features of HCMs, such as arrhythmias, DADs, and prolonged AP duration.

**DISCUSSION**

In the present study, we investigated the molecular and pathological mechanisms underlying the HCM-associated m.2336T>C mutation by generating a patient-specific iPSC-derived cardiomyocytes model. The HCM-iPSC-CMs not only maintained the original m.2336T>C mutation but also possessed the major properties of hypertrophied cardiomyocytes. We observed a significant reduction in the steady-state level of 16S rRNA and its binding proteins in HCM-iPSC-CMs compared with that in Ctrl-iPSC-CMs, suggesting that the m.2336T>C mutation impaired the stability of 16S rRNA and assembly of mitochondrial ribosomes. Interestingly, some mutations in genes encoding mitochondrial ribosome binding proteins were identified from HCM families (Galmiche et al., 2011; Smits et al., 2011; Carroll et al., 2013). The L156R mutation in MRPL44 affected the assembly of the large ribosomal subunit and stability of 16S rRNA, thereby leading to complex IV deficiency (Carroll et al., 2013). The Leu215Pro mutation in MRPS22 caused a decrease in 12S rRNA (Smits et al., 2011). Furthermore, the m.2336T>C mutation caused the defect of mitochondrial ETC complexes to transfer less H+ from the matrix into the intermembrane space, which formed the lower H+ potential difference and concentration gradient ($\Delta \psi_m$) across the mitochondrial inner membrane. This lower $\Delta \psi_m$ resulted in less proton motive force to generate ATP via complex V of the ETC. The reduction of the ATP/ADP ratio means a low ATP synthesis efficiency (Maldonado and Lemasters, 2014). We also observed more immature mitochondria with less cristae in HCM-iPSC-CMs than in Con-iPSC-CMs, similar to those in lymphoblastoid cell lines (Liu et al., 2014). Mitochondrial morphology has been shown to regulate cardiomyocyte differentiation and embryonic heart development (Kasahara et al., 2013; Hom et al., 2011). The defect of mitochondrial ultrastructure contributes to the pathogenesis of congestive heart failure complications (Arbustini et al., 1998; Wanet et al., 2015; Xu et al., 2013).

The mitochondrion is a major storage organism of Ca2+ and regulates the intracellular Ca2+ homeostasis with the SR (Santo-Domingo and Demaurex, 2010). Evidence of elevation in [Ca2+]i, was provided as an initiating factor in iPSC-CMs derived from HCM patients with the Arg663His mutation in MYH7 (Lan et al., 2013). Here, we observed a reduction of MCU and an elevation of [Ca2+]i, and SR Ca2+ stores, along with a significant decrease of $\Delta \psi_m$ in HCM-iPSC-CMs. The uptake of Ca2+ into the mitochondrial matrix is mediated by MCU, which is powered by the mitochondrial membrane potential (Ben-Hail et al., 2014; Kamer and Mootha, 2015). Functional exclusion of the mitochondrial compartment by MCU blockade caused a shift of Ca2+ to the SR (Ronchi et al., 2017). The lower $\Delta \psi_m$ caused by the m.2336T>C mutation forced less cytoplasmic Ca2+ into the mitochondrial matrix and resulted in increased [Ca2+]i. These results indicated that the mitochondrial dysfunctions might disrupt the Ca2+ homeostasis and induce the downstream Ca2+-dependent cardiac hypertrophy signaling pathways in HCM-iPSC-CMs. For example, elevated [Ca2+]i, can activate Ca2+-sensitive calcineurin via Ca2+/calmodulin (Hudson and Price, 2013) or mediate the activation of myocyte enhancer factor 2 (Molkentin et al., 1998) and thereby can cause HCM. Furthermore, HCM-iPSC-CMs exhibited some electrophysiological abnormalities (such as prolonged APD and increased DADs) and cellular arrhythmias. Generation of APs results from sequential activation and inactivation of ion (Na+, Ca2+, and K+) channels. The large, rapid influx of Na+ ($I_{\text{Na}}$) results in fast membrane depolarization in the AP upstroke. The inward flow of Ca2+ ($I_{\text{CaL}}$) through L-type
calcium channels (LCCs) leads to the plateau phase (Mortotti et al., 2012; Veerman et al., 2015). In this study, we identified a more voltage-positive shift of $I_{\text{CaL}}$ activation but little shift of $I_{\text{CaL}}$ inactivation. The more potential difference between steady-state activation and inactivation, increasing the total amount of Ca$^{2+}$ entry through the LCC channel during the plateau phase, would prolong the APD. $I_K$ is the primary determinant of AP repolarization, such as the efflux of K$^+$ ($I_{\text{K}}$) in a brief repolarization, and the rapid and slow delayed rectifier K$^+$ channels ($I_{\text{Kr}}$ and $I_{\text{Ks}}$) in membrane repolarization to its original state (Veerman et al., 2015). Here, the reduced $I_K$ would slow the repolarization to contribute to the prolonged APD in HCM-iPSC-CMs. In addition, Ca$^{2+}$ influx during the plateau phase triggers the massive release of SR Ca$^{2+}$ and influences the kinetic properties of $I_{\text{CaL}}$. The higher SR Ca$^{2+}$ content may promote diastolic Ca$^{2+}$ leakage with potential effects on APD. The HCM-iPSC-CMs with the MYH7 Arg442Gly mutation displayed prolonged APD, but not DAD (Han et al., 2014). We observed that HCM-iPSC-CMs with the m.2336T>C mutation exhibited both DAD and prolonged APD. The decreased $I_{\text{CaL}}$ together with $I_K$ might result in the prolongation of the APD at 30%, 50%, and 90% of the repolarization phase. These results might suggest the existence of multiple manifestations among these HCM-iPSC-CMs due to different pathogenic mutations. Ca$^{2+}$ homeostasis played an important role in the regulation of excitation-contraction coupling and development of cardiac arrhythmias (Berlin et al., 1989; Bers, 2008; Deferrari et al., 1995).

Abnormal energy metabolism is a common feature of HCM (Roscia et al., 2013). The mutant hearts in transgenic mice expressing the HCM-associated Lys104Glu mutation in the myosin regulatory light chain displayed significantly higher mitochondrial content with preserved overall architecture (Huang et al., 2014). Measurement of transgenic cardiomyocyte sections in transgenic rats overexpressing a truncated cardiac troponin T molecule revealed...
a significant increase in the mitochondrial fraction (Luedde et al., 2009). Cardiomyocytes from hypertrophic hearts showed a markedly increased number and reduced size of mitochondria (Pisano et al., 2016). These results indicated that the inefficient cellular ATP utilization and the consequently increased energy demand contributed to the pathogenesis of HCM with mutations in nDNA encoding sarcomeric genes (Ashrafian et al., 2003). Here, we further reported changes in mitochondrial biogenesis with a primary mtDNA defect. The m.2336T>C mutation led to a reduction of the ATP/ADP ratio, implying a lower ATP synthesis efficiency and fewer ATP products in each mitochondrion. The increased mtDNA copy number per nDNA and mitochondrial content in each cardiomyocyte were detected by qPCR and TEM. It can be considered as energy compensatory in HCM due to lower ATP synthesis efficiency by mtDNA mutations, similar to inefficient cellular ATP utilization by sarcomeric gene mutations.

Limitations to our study should be also noted. First, although Yamanaka factor-based reprogramming remains the most convenient way of generating iPSCs, the integration of retroviral vectors into the host genome potentially caused immunogenicity and tumorigenesis and greatly hindered its application in clinic (Takahashi and Yamanaka, 2016). Second, human iPSC-derived cardiomyocytes exhibit high phenotypic immaturity and variability, which presents some differences compared with adult cardiomyocytes (Sala et al., 2016). More optimal differentiation approaches and culture conditions will be tried in the future to improve the maturation of iPSC-CMs. Third, the AP was recorded from spontaneously beating cells and not from cells stimulated at a fixed frequency. APD values might then be a bit biased by the different baseline beating frequency.

In summary, our results demonstrate that the MT-RNR2 mutation results in mitochondrial dysfunctions and ultrastructure defects, which induced HCM-specific cellular and electrophysiological characteristics in iPSC-CMs. Furthermore, the MT-RNR2 mutation induced an increase of mitochondrial content to compensate for the energy-generating shortage. Our findings thus provide insight into the pathogenesis of HCM contributed by mtDNA mutations.

**EXPERIMENTAL PROCEDURES**

**Ethical Statement**
The study was approved by the Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine, China, and written informed consent was obtained from each participant before enrollment.

**Generation and Characterization of HCM-iPSCs**
The generation of patient-specific iPSCs from urine samples was performed (Zhou et al., 2012; Zhang et al., 2016). Characterization of iPSCs was performed as reported previously, including alkaline phosphatase staining, expression of endogenous pluripotent genes, silencing of exogenous transgenes, transgene integration, immunocytochemistry, karyotyping, DNA methylation, and in vitro and in vivo differentiation.

**Differentiation of iPSCs into Cardiomyocytes**
The established iPSC lines from HCM patients and the control group were differentiated directionally into cardiomyocyte lineages (iPSC-CMs) by monolayer myocardial differentiation protocols (Lian et al., 2012). The beating cardiomyocytes were picked up, dissociated, and seeded on coverslips for functional assays, such as calcium imaging, patch clamp, immunostaining, and more.

**Measurement of Cell Size**
Cell size measurements were performed by TNNI3 immunostaining as described previously, with modifications (Parra et al., 2014). Confocal image stacks were captured with a Zeiss LSM710 laser scanning confocal microscope, and the analysis software was Zen2011. Cell size was analyzed using the Imagej 3D Objects Counter plugin.

**ATP/ADP Measurements**
The ATP/ADP level in cells was measured using bioluminescent detection (ADP/ATP Ratio Assay Kit, Abcam) according to the manufacturer’s instructions. The cells were plated in 96-well microplates with RPMI 1640 medium containing 20% fetal bovine serum for 72 hr. The bioluminescent intensities were measured on a multi-mode microplate reader (Synergy H1 Hybrid, BioTek).

**Mitochondrial Membrane Potential Assay**
The mitochondrial membrane potential was measured using fluorescent detection (JC-10 Assay Kit, Abcam) according to the manufacturer’s instructions. The cells were cultured on 96-well, black-walled, clear-bottom plates and dyed with 50 μl of JC-10 solution. The fluorescence intensities (excitation/emission [Ex/Em] = 485/525 nm and Ex/Em = 540/590 nm) were measured on a multi-mode microplate reader (Synergy H1 Hybrid, BioTek).

**Measurement of Intracellular Ca2+**
[Ca2+]i, was measured as described previously (Liao et al., 2016). iPSC-CMs were dissociated and loaded in culture medium containing fura-2AM (Dojindo Laboratories). The calcium flux was measured using excitation at 340 nm and 380 nm in a fluorescence spectrometer (LS55, PerkinElmer Life Sciences). The intracellular Ca2+ concentrations were calculated using a fluorescence spectrometer measurement program.

**Calcium Imaging**
Changes in intracellular Ca2+ concentration were assessed with ratiometric calcium measurement using fura-2AM as described previously (Zou et al., 2017). iPSC-CMs were dissociated and seeded in gelatin-coated chambers (SPL, Korea). Cells were loaded with 5 μmol/L fura-2 AM in a bath solution at room temperature. Imaging was acquired in a BX51WI microscope (Olympus) with...
a 40× objective lens on an Andor DL-604M EMCCD camera. Data were collected using Macro-manager software.

Patch Clamping
The electrophysiological analysis, including single-cell AP, I_{Ca,L} and potassium currents, was performed by the whole-cell patch-clamp configuration (Axopatch-700A and MultiClamp 700B amplifier, Axon Instruments, Sunnyvale, CA) (Hamill et al., 1981). pClamp10.2 software (Axon Instruments, Molecular Devices) was used for data analysis.

Western Blotting Analysis
Twenty micrograms of various proteins were loaded on 12% SDS-PAGE, then electro-transferred to a polyvinylidene difluoride membrane and subjected to western blotting. The primary antibodies used for this experiment are listed in Table S5. Signals were detected using the CLINX ChemiScope and ECL system (CWBiO).

Quantitative Real-Time PCR
Total RNA preparations were obtained by using Trizol reagent (Invitrogen) from 1 × 10^7 cells. Quantitative real-time PCR, for mtDNA copy number, expression of mtDNA, endogenous pluripotent genes, and exogenous transgenes and more, was performed on an ABI PRISM 7900HT Sequence Detection System (Applied Biosystems). The forward and reverse primers for PCR amplification are shown in Table S6. Signals were detected using the CLINX ChemiScope and ECL system (CWBiO).

Statistical Analysis
Statistical analysis was carried out using Student's unpaired, two-tailed t test in Microsoft Excel. All data represent three control individuals (three clones) and one patient (three clones), with at least three independent experiments. Several replicates for each clone were performed in every independent experiment. n is the total replicates of each group. Data are represented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.

SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, seven figures, seven tables, and two movies and can be found with this article online at https://doi.org/10.1016/j.stemcr.2018.01.013.

AUTHOR CONTRIBUTIONS
Q.Y. conceived and designed the research. S.L., H.P., C.T., Y. Sun, Y. Song, X.Z., W.Y., X.W., D.L., Y.D., Q.M., C.X., Z.X., L.K., Y.F., X.X., and J.S. performed the experiments. Q.Y., W.H., and Z.L. analyzed the data and wrote the manuscript. F.H., N.Z., and D.Q. helped analyze the data and discuss the results.

ACKNOWLEDGMENTS
This work was supported by the National Basic Research Program of China (2014CB943001, 2012CB966804), the National Natural Science Foundation of China (31771398, 31571299, 81570216, 81470686), Zhejiang Provincial Natural Science Foundation of China (LY14C060004, LY14H140004), and the NIH (2R01CA139158). We thank Professor Min-Xin Guan at Zhejiang University School of Medicine for mentorship and support and Professor Xiaohang Yang at Zhejiang University School of Medicine for discussions. We also thank Dr. Nancy Linford at City of Hope National Medical Center for editing.

Received: May 14, 2017
Revised: January 16, 2018
Accepted: January 17, 2018
Published: February 15, 2018

REFERENCES
Alcalai, R., Seidman, J.G., and Seidman, C.E. (2008). Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. J. Cardiovasc. Electrophysiol. 19, 104–110.

Andreu, A.L., Checcarelli, N., Iwata, S., Shanske, S., and DiMauro, S. (2000). A missense mutation in the mitochondrial cytochrome b gene in a revisited case with histiocytoid cardiomyopathy. Pedia. Res. 48, 311–314.

Arbustini, E., Diegoli, M., Fasani, R., Grasso, M., Morbini, P., Bancieri, N., Bellini, O., Dal Bello, B., Pilotto, A., Magrini, G., et al. (1998). Mitochondrial DNA mutations and mitochondrial abnormalities in dilated cardiomyopathy. Am. J. Pathol. 153, 1501–1510.

Ashrafiain, H., Redwood, C., Blair, E., and Watkins, H. (2003). Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion. Trends Genet. 19, 263–268.

Bates, M.D., Bourke, J.P., Giordano, C., d’Amati, G., Turnbull, D.M., and Taylor, R.W. (2012). Cardiac involvement in mitochondrial DNA disease: clinical spectrum, diagnosis, and management. Eur. Heart J. 33, 3023–3033.

Ben-Hail, D., Palty, R., and Shoshan-Barmatz, V. (2014). Measurement of mitochondrial Ca_{2+} transport mediated by three transport proteins: VDAC1, the Na+/Ca_{2+} exchanger, and the Ca_{2+} uniporter. Cold Spring Harb. Protoc. 2014, 161–166.

Berlin, J.R., Cannell, M.B., and Lederer, W.J. (1989). Cellular-origins of the transient inward current in cardiac myocytes-role of fluctuations and waves of elevated intracellular calcium. Circ. Res. 65, 115–126.

Bers, D.M. (2008). Calcium cycling and signaling in cardiac myocytes. Annu. Rev. Physiol. 70, 23–49.

Bircket, M.J., Ribeiro, M.C., Kosmidis, G., Ward, D., Leitoginhuo, A.R., van de Pol, V., Dambrot, C., Devalla, H.D., Davis, R.P., Mastroberardino, P.G., et al. (2015). Contractile defect caused by mutation in MYBNPC3 revealed under conditions optimized for human PSC-cardiomyocyte function. Cell Rep. 13, 733–745.

Carroll, C.J., Isohanni, P., Pöyhönen, R., Euro, L., Richter, U., Brilhante, V., Götz, A., Lahtinen, T., Paetau, A., Pihko, H., et al. (2013). Whole-exome sequencing identifies a mutation in the mitochondrial ribosome protein MRPL44 to underlie mitochondrial infantile cardiomyopathy. J. Med. Genet. 50, 151–159.

Cherry, A.B., Gagne, K.E., McLoughlin, E.M., Baccei, A., Gorman, B., Hartung, O., Miller, J.D., Zhang, J., Zon, R.L., Ince, T.A., et al.
myocytes. Circulation (1995). Distinct patterns of calcium transients during early and delayed afterdepolarizations induced by isoproterenol in ventricular myocytes. Circulation 91, 2510–2515.

Finsterer, J., and Kothari, S. (2014). Cardiac manifestations of primary mitochondrial disorders. Int. J. Cardiol. 177, 754–763.

Folmes, C.D., Martinez-Fernandez, A., Perales-Clemente, E., Li, X., McDonald, A., Oglesbee, D., Hrstka, S.C., Perez-Terzic, C., Terzic, A., and Nelson, T.J. (2013). Disease-causing mitochondrial heteroplasmacy segregated within induced pluripotent stem cell clones derived from a patient with MELAS. Stem Cells 31, 1298–1308.

Fujikura, J., Nakao, K., Sone, M., Moguchi, M., Mori, E., Naito, M., Taura, D., Harada-Shiba, M., Kishimoto, I., Watanabe, A., et al. (2012). Induced pluripotent stem cells generated from diabetic patients with mitochondrial DNA A3243G mutation. Diabetologia 55, 1689–1698.

Galmiche, L., Serre, V., Beinat, M., Assouline, Z., Lebre, A.S., Chretien, D., Nietschke, P., Benes, V., Boddaert, N., Sidi, D., et al. (2011). Exome sequencing identifies MRPL3 mutation in mitochondrial cardiomyopathy. Hum. Mutat. 32, 1225–1231.

Hamalainen, R.H., Manninen, T., Koivumaki, H., Kislin, M., Otonkoski, T., and Suomalainen, A. (2013). Tissue- and cell-type-specific manifestations of heteroplasmic mtDNA 3243A>G mutation in human induced pluripotent stem cell-derived disease model. Proc. Natl. Acad. Sci. USA 110, E3622–E3630.

Hamill, O.P., Marty, A., Neher, E., Sakmann, B., and Sigworth, F.J. (1981). Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch. 391, 85–100.

Han, L., Li, Y., Tchao, J., Kaplan, A.D., Lin, B., Mich-Basso, J., Lis, A., Hassan, N., London, B., Bett, G.C., et al. (2014). Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells. Circul. 104, 258–269.

Hershberger, R.E., Cowan, J., Morales, A., and Siegfried, J.D. (2009). Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardio-myopathy. Circ. Heart Fail. 2, 253–261.

Hom, J.R., Quintanilla, R.A., Hoffman, D.L., Karen, M.B., Mokrentin, J.D., Sheu, S.S., and Porter, G.A., Jr. (2011). The permeability transition pore controls cardiac mitochondrial maturation and myocyte differentiation. Dev. Cell 21, 469–478.

Huang, W., Liang, J., Kazmierczak, K., Muthu, P., Duggal, D., Farman, G.P., Sorensen, L., Pozios, I., Abraham, T.P., Moore, J.R., et al. (2014). Hypertrophic cardiomyopathy associated Lys104Glu mutation in the myosin regulatory light chain causes diastolic disturbance in mice. J. Mol. Cell. Cardiol. 74, 318–329.

Hudson, M.B., and Price, S.R. (2013). Calcineurin: a poorly understood regulator of muscle mass. Int. J. Biochem. Cell Biol. 45, 2173–2178.

Inoue, H., Nagata, N., Kurokawa, H., and Yamanaka, S. (2014). iPS cells: a game changer for future medicine. EMBO J. 33, 409–417.

Jonckheere, A.L., Hogeveen, M., Nijtmans, L.G., van den Brand, M.A., Janssen, A.J., Diepstra, J.H., van den Brandt, F.C., van den Heuvel, L.P., Hol, F.A., Hofste, T.G., et al. (2008). A novel mitochondrial ATP8 gene mutation in a patient with apical hypertrophic cardiomyopathy and neuropathy. J. Med. Genet. 45, 129–133.

Kamer, K.J., and Mootha, V.K. (2015). The molecular era of the mitochondrial calcium uniporter. Nat. Rev. Mol. Cell Biol. 16, 545–553.

Kasahara, A., Cipolat, S., Chen, Y., Dorn, G.W., 2nd, and Scorrano, L. (2013). Mitochondrial fusion directs cardiomyocyte differentiation via calcineurin and Notch signaling. Science 342, 734–737.

Lan, F., Lee, A.S., Liang, P., Sanchez-Freire, V., Nguyen, P.K., Wang, L., Han, L., Yen, M., Wang, Y., Sun, N., et al. (2013). Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 12, 101–113.

Lian, X., Hsiao, C., Wilson, G., Zhu, K., Hazeltine, L.B., Azarir, S.M., Raval, K.K., Zhang, J., Kamp, T.J., and Palecek, S.P. (2012). Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc. Natl. Acad. Sci. USA 109, E1848–E1857.

Liao, Y., Lu, B., Ma, Q., Wu, G., La, X., Zhang, J., Shi, Y., Liu, D., Han, F., and Zhou, N. (2016). Human neuropeptide S receptor is activated via a Gαq protein-biased signaling cascade by a human neuropeptide S analog lacking the C-terminal 10 residues. J. Biol. Chem. 291, 7505–7516.

Liu, Z., Song, Y., Li, D., He, X., Li, S., Wu, B., Wang, W., Gu, S., Zhu, X., Wang, X., et al. (2014). The novel mitochondrial 16S rRNA 2336T>C mutation is associated with hypertrophic cardiomyopathy. J. Med. Genet. 51, 176–184.

Luedde, M., Flögel, U., Knorr, M., Grundt, C., Hippe, H.J., Brors, B., Frank, D., Haselmann, U., Antony, C., Voelkers, M., et al. (2009). Decreased contractility due to energy deprivation in a transgenic rat model of hypertrophic cardiomyopathy. J. Mol. Med. 87, 411–422.

Ma, H., Folmes, C.D.L., Wu, J., Morey, R., Mora-Castilla, S., Ocampo, A., Ma, L., Poulton, J., Wang, X., Ahmed, R., et al. (2015). Metabolic rescue in pluripotent cells from patients with mtDNA disease. Nature 524, 234–238.

Maldonado, E.N., and Lemasters, J.J. (2014). ATP/ADP ratio, the missed connection between mitochondria and the Warburg effect. Mitochondrion 19 (Pt A), 78–84.

Maron, B.J., Towbin, J.A., Thiene, G., Antzelevitch, C., Corrado, D., Arnett, D., Moss, A.J., Seidman, C.E., and Young, J.B. American Heart Association Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; Council on Epidemiology and Prevention (2006). Contemporary definitions and classification of the cardiomyopathies: an American heart association scientific statement from the council on clinical cardiology, heart failure and transplantation committee; quality of care and outcomes research and functional genomics and translational biology interdisciplinary working groups; and council on epidemiology and prevention. Circulation 113, 1807–1816.

Merante, E., Tein, I., Benson, L., and Robinson, B.H. (1994). Maternally inherited hypertrophic cardiomyopathy due to a novel
T-to-C transition at nucleotide 9997 in the mitochondrial tRNA-glycine gene. Am. J. Hum. Genet. 55, 437–446.

Molkentin, J.D., Lu, J.R., Antos, C.L., Markham, B., Richardson, J., Robbins, J., Grant, S.R., and Olson, E.N. (1998). A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93, 215–228.

Morita, H., Rehm, H.L., Menesses, A., McDonough, B., Roberts, A.E., Kucherlapati, R., Towbín, J.A., Seidman, J.G., and Seidman, C.E. (2008). Shared genetic causes of cardiac hypertrophy in children and adults. N. Engl. J. Med. 358, 1899–1908.

Morotti, S., Grandi, E., Summa, A., Ginsburg, K.S., and Bers, D.M. (2012). Theoretical study of L-type Ca2+ current inactivation kinetics during action potential repolarization and early afterdepolarizations. J. Physiol. 590, 4465–4481.

Parra, V., Verdejo, H.E., Iglewski, M., Del Campo, A., Troncoso, R., Jones, D., Zhu, Y., Kuzmicic, J., Pennanen, C., Lopez-Crisostó, C., et al. (2014). Insulin stimulates mitochondrial fusion and function in cardiomyocytes via the Akt-mTOR-NFkB-Opa-1 signaling pathway. Diabetes 63, 75–88.

Pisano, A., Cerbella, B., Perli, E., Pelullo, M., Bargelli, V., Preziuso, C., Mancini, M., He, L., Bates, M.G., Lucena, J.R., et al. (2016). Impaired mitochondrial biogenesis is a common feature to myocardial hypertrophy and end-stage ischemic heart failure. Cardiovasc. Pathol. 25, 103–112.

Ronchi, C., Torre, E., Rizzetto, R., Bernardi, J., Rocchetti, M., and Zaza, A. (2017). Late sodium current and intracellular ionic homeostasis in acute ischemia. Basic Res. Cardiol. 112, 12.

Rosca, M.G., Tandle, B., and Hoppl, C.L. (2013). Mitochondria in cardiac hypertrophy and heart failure. J. Mol. Cell. Cardiol. 55, 31–41.

Sala, L., Bellin, M., and Mummery, C.L. (2016). Integrating cardiomyocytes from human pluripotent stem cells in safety pharmacology: has the time come? Br. J. Pharmacol. 174, 3749–3765.

Santo-Domingo, J., and Demaurex, N. (2010). Calcium uptake mechanisms of mitochondria. Biochim. Biophys. Acta 1797, 907–912.

Santorelli, F.M., Mak, S.C., El-Schahawi, M., Casali, C., Shanske, S., Baram, T.Z., Madrid, R.E., and DiMauro, S. (1996). Maternally inherited cardiomyopathy and hearing loss associated with a novel mutation in the mitochondrial tRNA(lys) gene (G8363A). Am. J. Hum. Genet. 58, 933–939.

Shin, W.S., Tanaka, M., Suzuki, J., Hemmi, C., and Toyo-oka, T. (2000). A novel homoplasmic mutation in mtDNA with a single evolutionary origin as a risk factor for cardiomyopathy. Am. J. Hum. Genet. 67, 1617–1620.

Smits, P., Saada, A., Wortmann, S.B., Heister, A.J., Brink, M., Pfundt, R., Miller, C., Haas, D., Hantschmann, R., Rodenburg, R.J., et al. (2011). Mutation in mitochondrial ribosomal protein MRPS22 leads to Cornelia de Lange-like phenotype, brain abnormalities and hypertrophic cardiomyopathy. Eur. J. Hum. Genet. 19, 394–399.

Song, Y.R., Liu, Z., Gu, S.L., Qian, L.J., and Yan, Q.F. (2011). Advances in the molecular pathogenesis of hypertrophic cardiomyopathy. Yi Chuan 33, 549–557.

Takahashi, K., and Yamanaka, S. (2016). A decade of transcription factor-mediated reprogramming to pluripotency. Nat. Rev. Mol. Cell Biol. 17, 183–193.

Taylor, R.W., and Tumbull, D.M. (2005). Mitochondrial DNA mutations in human disease. Nat. Rev. Genet. 6, 389–402.

Taylor, R.W., Giordano, C., Davidson, M.M., d’Amati, G., Bain, H., Hayes, C.M., Leonard, H., Barron, M.J., Casali, C., Santorelli, F.M., et al. (2003). A homoplasmic mitochondrial transfer ribonucleic acid mutation as a cause of maternally inherited hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 41, 1786–1796.

Veerman, C.C., Kosmidis, G., Mummery, C.L., Casini, S., Verkerk, A.O., and Bellin, M. (2015). Immaturity of human stem-cell-derived cardiomyocytes in culture: fatal flaw or soluble problem? Stem Cells Dev. 24, 1035–1052.

Wallace, D.C., Singh, G., Lott, M.T., Hodge, J.A., Schurr, T.G., Lezza, A.M., Elsas, L.J., 2nd, and Nikoskelainen, E.K. (1988). Mitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy. Science 242, 1427–1430.

Wallace, D.C., and Fan, W. (2009). The pathophysiology of mitochondrial disease as modeled in the mouse. Genes Dev. 23, 1714–1736.

 Wanet, A., Arnould, T., Najimi, M., and Renard, P. (2015). Connecting mitochondria, metabolism and stem cell fate. Stem Cells Dev. 24, 1957–1971.

Ware, S.M., El-Hassan, N., Kahler, S.G., Zhang, Q., Ma, Y.W., Miller, E., Wong, B., Spicer, R.L., Craigen, W.J., Kozel, B.A., et al. (2009). Infantile cardiomyopathy caused by a mutation in the overlapping region of mitochondrial ATPase 6 and 8 genes. J. Med. Genet. 46, 308–314.

Wu, J., OCampo, A., and Belmonte, J.C. (2016). Cellular metabolism and induced pluripotency. Cell 166, 1371–1385.

Xu, X., Duan, S., Yi, F., OCampo, A., Liu, G.H., and Belmonte, J.C. (2013). Mitochondrial regulation in pluripotent stem cells. Cell Metab. 18, 325–332.

Yamanaka, S. (2007). Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell 1, 39–49.

Zeviani, M., Gellera, C., Antozzi, C., Rimoldi, M., Morandi, L., Viliani, F., Tiranti, V., and DiDonato, S. (1991). Maternally inherited myopathy and cardiomyopathy- association with mutation in mitochondrial-DNA transfer RNA(Leu/UUR). Lancet 338, 143–147.

Zhang, X., Li, S., Yang, W., Pan, H., Qin, D., Zhu, X., and Yan, Q. (2016). Mitochondrial disease-specific induced pluripotent stem cell models: generation and Characterization. Methods Mol. Biol. 1353, 322–342.

Zhang, X., Li, S., Yang, W., Qin, D., Yu, L., and Yan, Q. (2014). Patient-specific induced pluripotent stem cell models in mitochondrial diseases. Curr. Stem Cell Res. Ther. 9, 134–140.

Zhou, T., Benda, C., Dunzinger, S., Huang, Y., Ho, J.C., Yang, J., Wang, Y., Zhang, Y., Zhuang, Q., Li, Y., et al. (2012). Generation of human induced pluripotent stem cells from urine samples. Nat. Protoc. 7, 2080–2089.

Zou, W., Cheng, H., Li, S., Yue, X., Xue, Y., Chen, S., and Kang, L. (2017). Polymodal responses in C. elegans phasmid neurons rely on multiple intracellular and intercellular signaling pathways. Sci. Rep. 7, 42295.
Supplemental Information

Mitochondrial Dysfunctions Contribute to Hypertrophic Cardiomyopathy in Patient iPSC-Derived Cardiomyocytes with MT-RNR2 Mutation

Shishi Li, Huaye Pan, Chao Tan, Yaping Sun, Yanrui Song, Xuan Zhang, Wei Yang, Xuexiang Wang, Dan Li, Yu Dai, Qiang Ma, Chenming Xu, Xufen Zhu, Lijun Kang, Yong Fu, Xuejun Xu, Jing Shu, Naiming Zhou, Feng Han, Dajiang Qin, Wendong Huang, Zhong Liu, and Qingfeng Yan
SUPPLEMENTAL FIGURE LEGENDS

Figure S1. Generation and characterization of induced pluripotent stem cells. (A) Phase contrast photographs of H1 embryonic stem cells (ESCs), iPSCs derived from control participants (Con-iPSCs), and iPSCs derived from HCM patients (HCM-iPSCs), all grown on feeder layers. iPSCs at passage 10 or more are shown. Scale bar, 100 μm. The same cell lines were stained for alkaline phosphatase (AP). Scale bar, 100 μm. Immunofluorescence analysis for the presence of the pluripotency markers (TRA-1-60, TRA-1-81, Nanog, SSEA-3 and SSEA-4) are indicated; nuclei are stained in blue with DAPI. Scale bar, 50 μm. See also Figures S2A-S2E. (B) Quantitative PCR was performed to detect the expression of endogenous pluripotent genes and marker genes in three germ layers from *in vitro* HCM-iPSC embryoid bodies (HCM-iPSC-EBs) and Ctrl-iPSC-EBs. H1 ESCs were used as a control. Values refer to the respective undifferentiated pluripotent colonies. *OCT4* and *NANOG* were used as markers of pluripotency, whereas *AFP*, *GATA4*, and *SOX17* (endoderm), *TBX1* (mesoderm), and *PAX6* and *SOX1* (ectoderm) were used as markers of differentiation. (C) Teratoma produced by HCM-iPSCs and Con-iPSCs showing derivatives of ectoderm (pigmented epithelium), mesoderm (smooth muscle) and endoderm (gut epithelium). Scale bar, 20 μm.

Figure S2. Generation and characterization of induced pluripotent stem cells. (A) The expression of endogenous pluripotent genes of iPSCs. UCs are negative controls and H1 is positive control. (B) The silencing of exogenous transgenes of
iPSCs. UCs are negative controls and H1 is positive control. (C) Integration of the exogenous transgenes by semi-quantitative PCR. (D) The methylation of promoter regions in the Oct4 and Nanog genes of iPSCs by bisulfite sequencing analysis.

UCs are negative controls and H1 is positive control. (E) Karyotype analysis of HCM-iPSCs and Ctrl-iPSCs.

**Figure S3. Identification of m.2336T>C mutation in the MT-RNR2 gene.** Partial sequence chromatograms of the 16S rRNA gene from Con-UCs (A), Con-iPSCs (B), HCM-UCs (C) and HCM-iPSCs (D), respectively. The arrows indicate the location of the base change at position 2336.

**Figure S4. Representative immunostaining and quantification analyses of MLC2v and MLC2a.** (A) Representative immunostaining for MLC2v and MLC2a in HCM-iPSC-CMs and Con-iPSC-CMs. Nuclei are stained in blue with DAPI. (B) Quantification of single and double positive cells in HCM-iPSC-CMs (n=41) compared to Con-iPSC-CMs (n=65). Data represent three control individuals (3 clones) and one patient (3 clones) with three independent experiments. The n is the total replicates of each Group. Data are represented as mean ± SEM.

**Figure S5. Western blotting and quantification analyses of mitochondrial calcium uniporter (MCU).** VDAC is shown as a loading control. Data represent three control individuals (3 clones) and one patient (3 clones) with three independent experiments. Data are represented as mean ± SEM. ***P<0.001.

**Figure S6. Steady-state level of SR Ca^{2+} transport marker proteins.** (A) Western blotting and quantification analysis of SERCA, NCX, PLB, PLB-p. β-ACTIN is
shown as a loading control. (B) The PLB-p/PLB ratio in Con-iPSC-CMs and HCM-iPSC-CMs. Data represent three control individuals (3 clones) and one patient (3 clones) with three independent experiments. Data are represented as mean ± SEM. *P<0.05.

**Figure S7. Properties of K⁺ current (Iₖ) in HCM-iPSC-CMs.** (A) Representative traces for Iₖ current using whole cell patch-clamp from HCM-iPSC-CMs (n=28) and Con-iPSC-CMs (n=30). (B) Current-voltage (I-V) relationship of Iₖ was determined from -60 to +60 mV in 10 mV increments from HCM-iPSC-CMs (n=28) and Con-iPSC-CMs (n=30). (C) Mean peak of Iₖ in HCM-iPSC-CMs (n=28) and Con-iPSC-CMs (n=30). (D) Iₖ density-voltage relationship was determined from -60 to +60 mV in 10 mV increments from HCM-iPSC-CMs (n=28) and Con-iPSC-CMs (n=30). (E) Peak Iₖ density in HCM-iPSC-CMs (n=28) and Con-iPSC-CMs (n=30). Data represent three control individuals (3 clones) and one patient (3 clones) with three independent experiments. The n is the total replicates of each Group. Data are represented as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001.
EXPERIMENTAL PROCEDURES

Ethical Statement

The clinical evaluations and urine cells (epithelial-like cells detached from tubules) were obtained from HCM family members under informed consent and using procedures approved by the Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine, China.

Generation of HCM-iPSCs

The clinical evaluations and urine cells (epithelial-like cells detached from tubules) were obtained from HCM family members under informed consent and using procedures approved by the Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine, China. The generation and characterization of patient-specific induced pluripotent stem cells (iPSCs) from urine samples were performed as previously reported (Zhou et al., 2012; Zhang et al., 2016). Urine cells were cultured in REBM (Renal Epithelial Basal Medium, Lonza) medium containing SingleQuot Kit CC-4127 supplements (Lonza). pMX-based retroviruses (Addgene) with the reprogramming factors Oct-4, Sox-2, Klf-4, and c-Myc were infected into 5–10×10⁴ cells in a 6-well culture dish. After 3 or 4 days of transfection, 5×10⁴ cells were split onto a layer of feeder cells using half human embryonic stem cell (ESC) medium with 10 ng/mL basic fibroblast growth factors (Invitrogen) and half dFBS medium [(DMEM high glucose medium (Invitrogen) with 20% human defined fetal bovine serum (Hyclone)]. On day 5, 50 μg/ml Vitamin C (Sigma) and 1 mmol/L valproic acid (Merck)
were added; Vitamin C was maintained in the medium but valproic acid was removed on day 12. The medium was replaced with mTesR1 medium (StemCell) on day 12 to the end of the experiment. Colonies with an ESC-like appearance were picked up and expanded on feeders or mTesR1 medium with Matrigel (BD Biosciences). We defined this stage as passage one.

**iPSCs characterization**

Characterization of iPSCs, such as alkaline phosphatase (AP) staining, expression of endogenous pluripotent genes, silencing of exogenous transgenes, transgene integration, immunocytochemistry, karyotyping and DNA methylation, were performed as previously reported (Zhang et al., 2016). DNA was extracted using a DNeasy Tissue kit (Qiagen), and total RNA was extracted using Trizol (Invitrogen). Quantitative real-time PCR (qPCR) was performed using an ABI PRISM 7900HT Sequence Detection System (Applied Biosystems) and SYBR Premix EX Taq™ (Takara). The samples were analyzed in triplicate and β-actin values were used for normalization. Bisulfite sequencing technology was used to detect the methylation pattern of the promoter region of *Oct4* and *Nanog*. Immunofluorescence staining confirmed the expression of pluripotency markers in these iPSCs. Primary antibodies included Nanog (1:200, R&D), SSEA-3 (1:400, Developmental Studies Hybridoma Bank), SSEA-4 (1:100, Abcam), TRA-1-60 (1:100, Millipore), and TRA-1-81 (1:100, Millipore). The secondary antibodies included Alexa Fluor 488 goat anti-mouse IgM, Alexa Fluor 594 goat anti-rat IgM, Alexa Fluor 594 donkey anti-mouse IgG, and Alexa Fluor 594 donkey anti-
goat IgG (all from Invitrogen). A laser scanning confocal microscope LSM710 (Zeiss) was used to capture immunofluorescence staining images.

**In vitro and in vivo differentiation**

To determine the differentiation ability of human iPSCs *in vitro*, we used floating cultivation to form embryoid bodies (EBs), as previously reported (Zhang et al., 2016). iPSCs on feeders were treated with dispase (Invitrogen) and then collected by scraping. After centrifugation, cell pellets were re-suspended in human ESC medium without bFGF and grown for 8 days in non-adherent dishes. The formed EBs were then transferred to Matrigel-coated dishes to allow differentiation for another 8 days before RNA extraction. To test iPSC pluripotency *in vivo*, we injected 2×10⁶ iPSCs subcutaneously or intramuscularly into immunocompromised non-obese diabetic–severe combined immunodeficient mice (NOD-SCID) using procedures approved by the experimental animal welfare ethics committee of Zhejiang University, China. The tumors were sectioned after 8-10 weeks, fixed with PBS containing 4% paraformaldehyde and stained with hematoxylin/eosin (Zhang et al., 2016).

**Differentiation of iPSCs into cardiomyocytes**

Established iPSC lines from HCM patients and the control group were differentiated into cardiomyocyte lineages (iPSC-CMs) using monolayer differentiation protocols as described previously (Lian et al., 2012). iPSCs were seeded onto a Matrigel-coated cell-culture dish at 1-2×10⁵ cells/cm² in mTeSR1 supplemented with 5μmol/L ROCK
inhibitor (Y-27632, Sigma) (day-5) for 24h. Then, the cells were cultured in mTeSR1 medium, which was changed daily (day-4~day-1). At day 0, the cells were treated with CHIR99021 (12μmol/L, Selleck) in RPMI1640/B27-insulin for 24h. The medium was then changed to RPMI1640/B27-insulin (day1). IWP2 (5μmol/L, Tocris) was added at day 3 and then removed during the medium change on day 5. The cells were maintained in RPMI1640/B27 starting on day 7, and were subcultured every 3 days. The mature beating CMs were picked up, dissociated and seeded on coverslips for functional assays, such as calcium imaging, patch-clamp, immunostaining and more.

**Measurement of cell size**

Cell size measurements were performed as previously described (Parra et al., 2014). Cells were cultured on coverslips for 72 h, incubated for 1 h with Mitotracker Red (200 nmol/L) and maintained in RPMI 1640 medium. Then cells were fixed with RPMI 1640 medium containing 4% paraformaldehyde for 15 min, and 0.4% Triton X-100 for permeabilization for 15min. Nonspecific sites were blocked with 5% skimmed milk in PBS for 1 h and then the cells were incubated with anti-TNNI3 at 4°C overnight. The secondary antibody was Alexa-Fluor-488-conjugated anti-mouse-IgG. Confocal image stacks were captured with a Zeiss LSM710 laser scanning confocal microscope and the analysis software was Zen2011. Cell size was analyzed using the Image J-3D Object counter plug-in. Each experiment was performed at least three times and 30-50 cells per condition were quantified.
ATP/ADP measurements

The ATP/ADP level in cells was measured using bioluminescent detection (ADP/ATP Ratio Assay Kit, Abcam) according to the manufacturer’s instructions. The cells were plated in 96well microplates (Corning) with RPMI1640 medium containing 20% FBS for 72 hrs. The bioluminescent intensities were measured on multi-mode microplate reader (Synergy H1 Hybrid, BioTek). The ATP test mixture (100μL/well) was added to obtain Data A. Next, 50μL/well of Nucleotide Releasing Buffer was added to release ATP and ADP and obtain Data B and Data C. Finally, Data D was determined by adding the ADP test mixture. The ATP/ADP ratio = (Data B-Data A) / (Data D-Data C). Each experiment was repeated at least three times.

Mitochondrial membrane potential assay

The mitochondrial membrane potential was measured using fluorescence detection (JC-10, Abcam) according to the manufacturer’s instructions. iPSC-CMs were cultured on 96-well black-walled clear-bottom plates for 48 hrs in mTeSR medium and RPMI1640 medium with 20% FBS, respectively. After the above cells were incubated with 100 μL fresh medium for 30 min and dyed with 50 μL JC-10 solution for 30min, the fluorescence intensities (Ex/Em=485/525nm and Ex/Em=540/590nm) were measured on multi-mode microplate reader (Synergy H1 Hybrid, BioTek). The ratio between monomeric (Em=590 nm) and aggregate (Em=525 nm) forms of JC-10 represents the change in the mitochondrial membrane potential. A high ratio indicates a high mitochondrial membrane potential.
Measurement of intracellular Ca$^{2+}$

The intracellular Ca$^{2+}$ concentrations were measured as described previously with slight modifications (Liao et al., 2016). iPSC-CMs were dissociated and loaded in a culture medium containing 5 µmol/L Fura-2 acetoxymethylester (Fura-2AM, Dojindo Laboratories) at 37°C for 30min and then washed to remove extracellular Fura-2AM. They were then resuspended in Hanks’ balanced salt solution (140 mmol/L NaCl, 5 mmol/L KCl, 10 mmol/L HEPES, 1 mmol/L CaCl$_2$, 1 mmol/L MgCl$_2$, 1 mg/ml glucose, pH7.4) at a concentration of 3×10$^7$ cells/mL. The calcium flux was measured using excitation at 340 nm and 380 nm in a fluorescence spectrometer (LS55, PerkinElmer Life Sciences). Calibration was performed using 0.1% Triton X-100 for total fluorophore release and 10 mmol/L EGTA to chelate the free Ca$^{2+}$. The intracellular Ca$^{2+}$ concentrations were calculated using a fluorescence spectrometer measurement program.

Calcium Imaging

Calcium imaging were performed as described previously with slight modifications (Zou et al., 2017). iPSC-CMs were seeded on gelatin-coated glass coverslips for 2 days. Cells were dissociated and loaded with 5 µmol/L Fura-2 AM (Dojindo Laboratories) in bath solution containing 0.01% pluronic F127 for 30 min at room temperature, and washed 5 times with bath solution. Imaging was acquired in an Olympus microscope (BX51WI) with a 40 × objective lens on an Andor DL-604M EMCCD camera. Data
was collected using the Macro-manager software. Fura-2 was excited by a Lambda XL light source and fluorescent signals were collected at a rate of 1 Hz. The fluorescence ratio \( F(\lambda_{\text{ex}340 \text{ nm}})/F(\lambda_{\text{ex}380 \text{ nm}}) \) was calculated and imaging data were analyzed using Imaging J. The bath solution contained: 140 mmol/L NaCl, 5 mmol/L KCl, 2 mmol/L MgCl\(_2\), 1.8 mmol/L CaCl\(_2\), 10 mmol/L HEPES, 10 mmol/L glucose.

**Caffeine treatment of iPSC-CMs**

Cells were perfused with PBS containing 1.8 mmol/L Ca\(^{2+}\) and 2 mmol/L Mg\(^{2+}\) and paced at 1Hz to view regular transients. A pulse of 20 mmol/L stock caffeine solution was added after 1 minute recording.

**Measurement of L-type Ca\(^{2+}\) currents**

The L-type Ca\(^{2+}\) currents \( (I_{\text{Ca}L}) \) were recorded using whole-cell patch-clamp (Axopatch-700A and MultiClamp 700B amplifier, Axon Instruments, Sunnyvale, CA), as previously described (Hamill et al., 1981). The pipette electrode (2.5-4.5 MΩ) was filled with a solution containing 120 mmol/L CsCl, 5 mmol/L Na\(_2\)-ATP, 5 mmol/L MgCl\(_2\), 10 mmol/L EGTA, and 5 mmol/L HEPES, pH 7.2. The external solution contained 140 mmol/L NaCl, 1 mmol/L MgCl\(_2\), 1.8 mmol/L CaCl\(_2\), 5 mmol/L CsCl and 10 mmol/L HEPES (pH 7.4). \( I_{\text{Ca}L} \) was elicited by a single 200 ms voltage pulse to various test potentials from the holding potential of -40 mV at a frequency of 0.1Hz. The recordings were initiated 5 min after the patch break, to allow for equilibration of the patch pipette solution with the intracellular milieu. The current-voltage (I/V)
relationship of $I_{CaL}$ was obtained by plotting the peak current amplitude in response to voltage pulses to potentials between -40 mV and +60 mV from the holding potential in 10 mV increments. The data was then analyzed with Lab Chart8 (AD Instruments).

**Current-voltage (I-V) relationship of $I_{CaL}$**

The current-voltage (I-V) relationship of $I_{CaL}$ was determined by applying test pulses (100 ms) from -60 to +50 mV in 10 mV increments at a frequency of 0.2 Hz. Prepulses from a holding potential of -80 to -40 mV (P, duration: 50 ms) along with TTX (10 mmol/L) were applied to inactivate Na$^+$ currents. The prestep to -40 mV was also applied to inactivate the T-type Ca$^{2+}$ current.

**Measurement of K$^+$ currents**

For recording K$^+$ currents the extracellular solution contained: 135 mmol/L N-methyl-D-glucamine (NMDG) chloride, 5 mmol/L KCl, 3.6 mmol/L CaCl2, 1 mmol/L MgCl2, 3 mmol/L NiCl2, and 10 mmol/L HEPES, pH adjusted to 7.40 at 37°C with NMG. The intracellular solution contained: 50 mmol/L KCl, 80 mmol/L K-aspartate, 1 mmol/L MgCl2, 3 mmol/L MgATP, 10 mmol/L EGTA, and 10 mmol/L HEPES, pH adjusted to 7.40 with NMDG. Depolarization-activated outward K$^+$ currents were elicited by a family of 500 ms depolarizations from a –80 mV holding potential to voltages ranging from –60 to +60 mV (10 mV steps).

**Steady-state activation and inactivation of $I_{CaL}$**
Steady-state activation was determined by stepping to various prepulse voltages (10 mV increments) levels from -60 to +20 mV for 100 ms from a holding potential of -80 mV before repolarizing to a fixed test pulse at -50 mV. Steady-state inactivation was determined by stepping to various prepulse voltages (-60 to +40 mV, 10 mV increments) for 5 s before depolarization to a fixed test potential of +10 mV for 100 ms to evoke channel opening. There was a 5 ms interpulse interval that enabled the resetting of the activation gate between the end of the prepulse and the beginning of the test pulse. Both steady-state activation and inactivation curves were fitted with a Boltzmann function (\(G=A2+(A1-A2)/(1+\exp((V1/2-x)/k)\)) that describes conductance (\(G\)) as a function of the potential (\(x\)). \(V1/2\) is half-activating or half inactivating potential, and \(k\) is the slope factor.

**Action potential analysis**

For single-cell action potential analysis, the whole-cell patch clamp configuration (Axopatch-700A and MultiClamp 700B amplifier, Axon Instruments, Sunnyvale, CA) (Hamill et al., 1981) was used. Cells were digested at 37°C for 30 min with 1 mg/ml collagenase B (Roche) and seeded for 2 days on gelatin-coated glass coverslips. For action potential recording, patch pipettes (3-5 MΩ) were filled with solutions containing 10 mmol/L HEPES, 120 mmol/L KCl, 1 mmol/L MgCl₂, 3 mmol/L Mg-ATP and 10 mmol/L EGTA, (pH 7.3), and a bath solution containing 10 mmol/L HEPES, 140 mmol/L NaCl, 5.4 mmol/L KCl, 1.8 mmol/L CaCl₂, 10 mmol/L glucose, and 1 mmol/L MgCl₂ (pH 7.4). The MultiClamp 700B Amplifier, Digidata 1440A analog-to-digital
converter and pClamp10.2 software (Axon Instruments/ Molecular Devices) were used for data amplification, acquisition and analysis.

**Western blot analysis**

Twenty micrograms of proteins obtained from iPSCs and iPSC-CMs were denatured and loaded on 12% SDS-PAGE (sodium dodecyl sulfate polyacrylamide gels). Afterward, the proteins were electro-transferred to polyvinylidene difluoride (PVDF) membrane and subjected to Western blotting. Membranes were blocked in Tris-Buffered Saline and Tween20 (TBST) (150 mmol/L NaCl, 10 mmol/L Tris–HCl, pH 7.5 and 0.1% (v/v) Tween 20) containing 5% (w/v) milk, then incubated with the corresponding primary and secondary antibodies. The primary antibodies used for this experiment were the ND5 (1:1000, Abcam), COII (1:2000, Abcam), CYTB (1:1000, Sigma), ATP8 (1:200, Santa Cruz), ANF (1:2000, Abcam), BNP (1:2000, Abcam), TNNI3 (1:2000, Abcam), α-ACTIN (1:500, Immunoway), MLC2v (1:1000, Abcam), MLV2a (1:500, Proteintech), RyR (1:1000, Abcam), PLB (1: 1000, Abcam), PLB-p (1:500, Abcam), SERCA2 (1:500, Abcam), MCU (1:1000, Abcam), NCX (1:1000, Abcam), β-ACTIN (1:1000, Proteintech) and VDAC (1:1000, Abcam). Peroxidase Affini Puregoatanti-mouse IgG and goatanti-rabbit IgG (Jackson) were used as a secondary antibody and protein signals were detected using the CLINX chemiscope and ECL system (CWBIO).

**Quantitative real-time PCR**
Total RNA preparations were obtained by using Trizol reagent (Invitrogen) from $1\times10^7$ cells as described elsewhere. One microgram of total RNA was reverse transcribed to cDNA using PrimeScript RT reagent Kit (Takara). The reaction system was the followed SYBR Premix EX TaqTM (Takara) instructions. The forward and reverse primers for PCR amplification are shown in supplemental table 1. GAPDH or VDAC served as an endogenous control. The quantitative real-time PCR was performed on an ABI PRISM 7900HT Sequence Detection System (Applied Biosystems). The relative amount of mRNA to endogenous control was calculated using the Ct cycle method as following formula: $\Delta\Delta Ct=[Ct(\text{target gene})−Ct(\text{control gene})]_{\text{target cell}} − [Ct(\text{target gene})−Ct(\text{control gene})]_{\text{reference cell}}$.

Quantification of mtDNA copy number

The mtDNA copy number was quantified as described previously (Venegas et al., 2012). A 1241bp section of the human $\beta$-globin gene and a 1724bp sequence of mtDNA located within the 16S rRNA gene was inserted into the cleaved blunt-ended Hind III and Ava I restriction sites of the pCR plasmid, respectively. The resultant plasmid pCR II (6073bp) was verified as having only one copy of each insert by restriction enzyme digestion and DNA sequencing. The relative mtDNA copy numbers were measured by quantitative real-time PCR and corrected by measurement of the nuclear DNA. The primers for the $MT-RNR2$ gene were 5’-GCACACCCCGTCTATGTAGCAA-3’ and 5’-GATTTAGAGGGTTCTGTGGGCA-3’. The primers for the nuclear $\beta$-globin gene were 5’-
AGAAACTGGGCAATGGAGACA-3’ and 5’-ATGAGCCTTCACCTTAGGGTTG-3’. The quantitative real-time PCR was performed using an ABI PRISM 7900HT Sequence Detection System (Applied Biosystems) and SYBR Premix EX Taq™ (Takara). Sample mtDNA content (mtDNA copies per cell) were calculated using the following formula:

\[ \text{mtDNA copies per cell} = \left( \frac{\text{MT-RNR2 gene copies}}{\beta\text{-globin gene copies}} \right) \times 2 \]

**Mutational analysis of mitochondrial genome**

Genomic DNA was isolated from the iPSCs of HCM patients and healthy unrelated individuals using DNeasy Tissue kit (Qiagen). The entire mtDNA were PCR amplified in 24 overlapping fragments by use of sets of the light-strand and heavy-strand oligonucleotide primers, as described previously (Liu et al., 2014). Each fragment was purified and subsequently analyzed by direct sequencing in an ABI 3730xl automated DNA sequencer using the Big Dye Terminator Cycle sequencing reaction kit. The resultant sequence data was compared with the revised Cambridge reference sequence (Genbank accession No. NC_001807) (Andrews et al., 1999). The published data on [http://www.mtdb.igp.uu.se/](http://www.mtdb.igp.uu.se/) was used to determine the allelic frequency of the identified variants.

**Statistical analysis**

Statistical analysis was carried out using the Student’s unpaired, two-tailed t-test contained in the Microsoft-Excel program. In Figure Legends, all data represent three
control individuals (3 clones) and one patient (3 clones) with at least three independent experiments. Several replicates for each clone were performed in every independent experiment. The n is the total replicates of each Group. Data are represented as mean ± SEM. *\(P<0.05\), **\(P<0.01\), ***\(P<0.001\).
Supplemental References

Andrews RM, Kubacka I, Chinnery PF, Lightowlers RN, Turnbull DM, Howell N. (1999). Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA. Nat Genet. 23:147.

Venegas V and Halberg MC. (2012). Measurement of mitochondrial DNA copy number. Methods Mol Biol. 837:327-35.
Figure S1.
Figure S2.
Figure S3.
Figure S4.

A

Con-iPSC-CMs

HCM-iPSC-CMs

B

% Stained Cells

MLC2a | MLC2v | Double +

Con-iPSC-CMs | HCM-iPSC-CMs
Figure S5.
Figure S6.
Figure S7.
**Table S1.** Summary for clinical features of HCM family members

| Ground  | Family Member | Gender (M/F) | Age (years) | MT-RNR2 Genotype | Symptoms | MLVWT (mm) | IVS/LPW |
|---------|----------------|--------------|-------------|------------------|----------|------------|---------|
| Maternal | II-1            | F            | 59          | m.2336T>C        | HCM      | 26.8       | 3.21    |
| Members  | II-3            | M            | 49          | m.2336T>C        | HCM      | 38.7       | 2.93    |
|         | III-1           | M            | 38          | m.2336T>C        | HCM      | 46.6       | 2.86    |
|         | III-3           | M            | 32          | m.2336T>C        | HCM      | 37.4       | 3.99    |
| Non-maternal | II-2        | M            | 57          | Wild type        | Normal   | 10.2       | 1.17    |
| Members  | II-4            | F            | 48          | Wild type        | Normal   | 9.6        | 1.22    |
|         | III-2           | F            | 30          | Wild type        | Normal   | 9.5        | 1.19    |
|         | III-4           | F            | 31          | Wild type        | Normal   | 8.5        | 1.23    |
|         | IV-1            | F            | 13          | Wild type        | Normal   | 8.2        | 1.28    |
|         | IV-2            | M            | 8           | Wild type        | Normal   | 8.2        | 1.12    |

*MLVWT, maximum left ventricular wall thickness; IVS, interventricular septum thickness; LPW, left posterior wall thickness.*
**Table S2. mtDNA variants of UCs and iPSCs from HCM patient**

| Gene      | Position | HCM-UC | HCM-iPSC7P10 | HCM-iPSC7P23 | HCM-iPSC7P33 |
|-----------|----------|--------|--------------|--------------|--------------|
| **D-loop** |          |        |              |              |              |
|           | 16223    | C > T  | C > T        | C > T        |
|           | 16295    | C > T  | C > T        | C > T        |
|           | 16519    | T > C  | T > C        | T > C        |
|           | 73       | A > G  | A > G        | A > G        |
|           | 146      | T > C  | T > C        | T > C        |
|           | 199      | T > C  | T > C        | T > C        |
|           | 489      | T > C  | T > C        | T > C        |
| **12S rRNA** |        |        |              |              |              |
|           | 750      | A > G  | A > G        | A > G        |
| **16S rRNA** |        |        |              |              |              |
|           | 2336     | T > C  | T > C        | T > C        |
|           | 2706     | A > G  | A > G        | A > G        |
| **ND1**   |          |        |              |              |              |
|           | 3882     | G > A  | G > A (syn)  | G > A (syn)  |
|           | 4071     | C > T  | C > T (syn)  | C > T (syn)  |
| **ND2**   |          |        |              |              |              |
|           | 4769     | A > G  | A > G (syn)  | A > G (syn)  |
|           | 4850     | C > T  | C > T (syn)  | C > T (syn)  |
| **ND3**   |          |        |              |              |              |
|           | 5894     | A>C    | A>C          | A>C          |
| **CO1**   |          |        |              |              |              |
|           | 6455     | C > T  | C > T (syn)  | C > T (syn)  |
|           | 7028     | C > T  | C > T (syn)  | C > T (syn)  |
| **ATP6**  |          |        |              |              |              |
|           | 8701     | A > G  | A > G (Thr-Ala) | A > G (Thr-Ala) |
|           | 8860     | A > G  | A > G (Thr-Ala) | A > G (Thr-Ala) |
| **COIII** |          |        |              |              |              |
|           | 9266     | G > A  | G > A (syn)  | G > A (syn)  |
|           | 9540     | T > C  | T > C (syn)  | T > C (syn)  |
|           | 9824     | T > C  | T > C (syn)  | T > C (syn)  |
| **ND4**   |          |        |              |              |              |
|           | 10398    | A > G  | A > G (Thr-Ala) | A > G (Thr-Ala) |
|           | 10400    | C > T  | C > T (syn)  | C > T (syn)  |
| **ND5**   |          |        |              |              |              |
|           | 12372    | G > A  | G > A (syn)  | G > A (syn)  |
|           | 13759    | G > A  | G > A (Ala-Thr) | G > A (Ala-Thr) |
| **CYTB**  |          |        |              |              |              |
|           | 14766    | C > T  | C > T (Thr-Ile) | C > T (Thr-Ile) |
|           | 14783    | T > C  | T > C (syn)  | T > C (syn)  |
|           | 15043    | G > A  | G > A (syn)  | G > A (syn)  |
|           | 15301    | G > A  | G > A (syn)  | G > A (syn)  |
|           | 15326    | A > G  | A > G (Thr-Ala) | A > G (Thr-Ala) |
|           | 15364    | C > T  | C > T (syn)  | C > T (syn)  |
**Table S3.** Steady-state activation and inactivation parameters of $I_{CaL}$ recorded in Con-iPSC-CMs or HCM-iPSC-CMs

|                  | Steady-state activation | Steady-state inactivation |
|------------------|-------------------------|---------------------------|
|                  | $V_{1/2}$ (mV) | k   | n  | $V_{1/2}$ (mV) | k   | n  |
| Con-iPSC-CMs     | -28.6±1.5       | 6.0±0.7 | 25 | -41.0±0.8       | 5.8±0.2 | 25 |
| HCM-iPSC-CMs     | -23.6±1.6*      | 7.3±0.5 | 23 | -40.1±0.6       | 5.6±0.2 | 23 |
Table S4. Electrophysiological parameters of iPSC-CMs

|                         | Con-iPSC-CMs    | HCM-iPSC-CMs   | p-Value |
|-------------------------|-----------------|----------------|---------|
| Beating rate (BPM)      | 68.4±2.1 (n=39) | 54.0±2.8 (n=34)| 0.0062  |
| Cm (pF)                 | 21.9±1.6 (n=39) | 46.4±4.9 (n=34)| 0.0005  |
| Tau (μs)                | 190.0±17.4 (n=39)| 437.6±76.2 (n=34)| 0.0008  |
| RMP (mV)                | -50.2±1.3 (n=40)| -55.5±0.8 (n=43)| 0.0806  |
| APA (mV)                | 90.2±1.4 (n=40) | 92.7±2.5 (n=43)  | 0.3846  |
| Max dV/dt (mV/s)        | 1250±764.9 (n=40)| 11917±597.8 (n=43)| 0.5480  |
| APD30 (ms)              | 394.2±18.7 (n=40)| 496.4±24.3 (n=43)| 0.0012  |
| APD50 (ms)              | 484.5±19.6 (n=40)| 577.7±30.1 (n=43) | 0.0051  |
| APD90 (ms)              | 582.3±19.6 (n=40)| 669.3±30.4 (n=43) | 0.0084  |

Cₘ, Cell electric capacitance; RMP, resting membrane potential; APA, action potential amplitude; Max dV/ds, maximal rate of depolarization; APD₃₀, APD at 30% of repolarization; APD₅₀, APD at 50% of repolarization; APD₉₀, APD at 90% of repolarization. Values are the means±SEM.
| Antibody   | Antigen                                      | Company   | Cat. No.   |
|------------|----------------------------------------------|-----------|------------|
| Anti-ANF   | Atrial natriuretic factor                    | Abcam     | ab191398   |
| Anti-BNP   | Brain natriuretic peptide                   | Abcam     | ab92500    |
| Anti-TNNI3 | Troponin I type 3 cardiac                    | Abcam     | ab52862    |
| Anti-α-ACTIN | alpha-cardiac muscle actin            | Immunoway | YT5110     |
| Anti-MLC2v | Ventricular myosin light chain              | Abcam     | ab92721    |
| Anti-MLC2a | Atrial myosin light chain 2                 | Proteintech | 17283-1-AP |
| Anti-NCX   | Na(+)/Ca(2+)-Exchange Protein               | Abcam     | ab177952   |
| Anti-RyR   | Ryanodine receptor                          | Abcam     | ab2868     |
| Anti-PLB   | Phospholamban                               | Abcam     | ab2865     |
| Anti-PLB-p | Phospholamban (phospho S16)                 | Abcam     | ab15000    |
|            | Sarcoplasmic/endoplasmic reticulum          |           |            |
| Anti-SERCA2 | calcium ATPase 2                             | Abcam     | ab150435   |
| Anti-VDAC  | Voltage dependent anion channel             | Abcam     | ab14734    |
| Anti-MRPL19| Mitochondrial ribosomal protein L19         | Abcam     | ab218978   |
| Anti-MRPL23| Mitochondrial ribosomal protein L23         | Abcam     | ab174791   |
| Anti-MT-ND5| Mitochondrial NADH dehydrogenase 5         | Abcam     | ab92624    |
| Anti-MT-CYB| Mitochondrial cytochrome b                  | Abcam     | ab81215    |
| Anti-MT-COX2| Mitochondrial cytochrome c oxidase 2       | Abcam     | ab79393    |
| Anti-MT-ATP8| Mitochondrial ATP synthase 8               | Santa Cruz | SC-84231 |
| Anti-MCU   | Mitochondrial calcium uniporter             | Abcam     | ab45167    |
| Anti-β-ACTIN | Beta cytoskeletal actin                   | Proteintech | 66009-1-Ig |

*Table S5. Information of antibodies in the study*
**Table S6. Primers for quantitative PCR**

| Gene      | Forward                     | Sequence (5’→3’)                      |
|-----------|----------------------------|---------------------------------------|
| GAPDH     | Forward                     | CAGGGCTGCTTTTTAACTCTTGTGA            |
| 16S rRNA  | Reverse                     | CATGGGTGGAATCATATTGGGAAC              |
| DNS       | Forward                     | GCAACCCGCCTATGTAGCAAA                |
| CYTB      | Reverse                     | GATTTAGAGGGTTCTGTGGGCA               |
| COX2      | Forward                     | CGCTATGACATCGACATGACCAAGT             |
| ATP8      | Reverse                     | ACCGATACAAAGTGTACGGCTTGGA            |
| MRPL19    | Forward                     | AGCAACACTCCACCTCTTATTTGGT            |
| MRPL23    | Reverse                     | CATGGGTGGAATCATATTGGGAAC              |
| RPLP0     | Forward                     | GGTGTCAGCTTGACTTAAC                  |
| 12S rRNA  | Reverse                     | GATCTGGGAACGTGAAGGTCT                |
| VDAC      | Forward                     | GCTTACTGGTGCTCCCGATTCA               |
| ACTB      | Reverse                     | GATCTGGGAACGTGAAGGTCT                |
| OCT4      | Forward                     | CCAGGAGATTCACTGCTGTCGA               |
| SOX2      | Reverse                     | GGAGCTTCCCACCGTTAAGA                |
| REX1      | Forward                     | GGTGTCAGCTTGACTTAAC                  |
| Tg-OCT4   | Reverse                     | GGTGTCAGCTTGACTTAAC                  |
| Tg-SOX2   | Forward                     | TGGTGACCTCCTCTTACAGT                 |
| Tg-KLF4   | Reverse                     | TGGTGACCTCCTCTTACAGT                 |
| Tg-C-MYC  | Forward                     | CCTCGTCGACGTAGAAATAC                 |
| Reagents                        | Company | Cat. No. |
|--------------------------------|---------|----------|
| pMX-h-Oct4                     | Addgene | 17217    |
| pMX-h-Sox2                     | Addgene | 17218    |
| pMX-h-Klf4                     | Addgene | 17219    |
| pMX-h-c-Myc                    | Addgene | 17220    |
| pMX-GFP                        | Addgene | 14567    |
| PCL-ECO                        | Addgene | 12371    |
| REGM™ Renal Epithelial Cell Growth Medium | Lonza    | CC-3191  |
| REGM SingleQuot Kit Suppl. & Growth Factors | Lonza    | CC-4127  |
| Primocin                       | Invivogen | ant-pm-1 |
| DMEM/HG                        | Gibco   | C11995500BT |
| DMEM/F12                       | Gibco   | C11330500BT |
| FBS                            | PAA     | A15-101  |
| Knockout serum replacement     | Gibco   | 10828-028 |
| NEAA                           | Gibco   | 11140-050 |
| GlutaMAX                       | Gibco   | 35050-061 |
| 0.1% Gelatin                   | millipore | ES-006-B |
| MycoAlert®Mycoplasma Detection Kit | Lonza    | LT07-218 |
| 2-Mercaptoethanol              | Gibco   | 21985-023 |
| bFGF                           | Invitrogen | 13256-029 |
| Dispase                        | Gibco   | 17105-041 |
| Collagenase IV                 | Gibco   | 17104-019 |
| Vc                             | Sigma   | 49752-10G |
| VPA                            | CALBIOCHEM | 676380 |
| mTeSR1                         | STEMCELL | #05850  |
| Matrigel                       | BD      | 354277   |
| REGM™ Renal Epithelial Cell Growth Medium | Lonza    | CC-3191  |
| Knockout serum replacement     | Gibco   | 10828-028 |
| B27-insulin                    | Gibco   | A1895601 |
| B27                            | Gibco   | 17504044 |
| CHIR99021                      | Selleck | CT99021  |
| IWP2                           | Tocris  | 3533     |
| Y-27632                        | Sigma   | Y0503    |
| Accutase                       | STEMCELL | #07920  |
| Collagenase B                  | Roche   | 11088815001 |